> ## Content Index
> Fetch the complete content index at: https://www.pennystocks.news/llms.txt
> Use this file to discover other available public pages before exploring further.

# Vogenx Raises $81.3 Million in Nasdaq Initial Public Offering
- URL: https://www.pennystocks.news/vogenx-81-3-million-initial-public-offering/
- Published: 2026-08-17T23:23:12.000Z
- Updated: 2026-08-17T23:23:12.000Z
- Description: Clinical-stage biopharmaceutical company Vogenx sold 6,250,000 shares at $13.00 each in an IPO that closed on August 13, 2026. JonesTrading acted as sole book-running manager.
- Author: PennyStocksNews Team
- Tags: nasdaq, ticker-vogx

JonesTrading Institutional Services LLC NASDAQ: VOGX 

Vogenx, Inc. sold **6,250,000 shares at $13.00 each for gross proceeds of about $81.3 million** in its initial public offering, according to an announcement from JonesTrading Institutional Services, which acted as sole book-running manager on the deal.

The price came in **at the high end of the proposed range**, the underwriter said. All of the shares in the offering were sold by the company itself, meaning no existing holders cashed out and the full gross amount goes to Vogenx before underwriting discounts, commissions and other expenses are deducted. The release did not state net proceeds, the underwriting discount, or whether an over-allotment option exists.

The stock **began trading on the Nasdaq Capital Market on August 12, 2026** under the ticker VOGX. The offering closed the following day, August 13.

Vogenx describes itself as a clinical-stage biopharmaceutical company working on treatments for serious diseases tied to dysfunctions in human metabolism. Chief executive James Green said the company is **targeting PBH and gastroparesis** — post-bariatric hypoglycemia, a condition in which blood sugar drops sharply after weight-loss surgery, and a disorder in which the stomach empties too slowly. "We are now well-capitalized to further the development of therapeutics," Green said in the release.

Beyond those two indications, **the announcement gave no detail on Vogenx's pipeline**: no trial phases, no timelines for data, no cash position before the raise and no operating burn rate. Clinical-stage biotechnology companies carry no product revenue by definition, so the size of the raise relative to annual spending is the figure that determines how long the money lasts. That comparison cannot be made from the material provided.

Nor does the release disclose the share count after the offering. Without it, the 6.25 million new shares cannot be measured against the existing base to gauge how much of the company was sold, or what the implied market capitalisation is at the $13.00 offer price.

Readers should note the source of the information. **The announcement was issued by JonesTrading, not by Vogenx**, and it functions largely as a business-development notice for the bank's investment banking arm. Alan Hill, chief executive of JonesTrading, framed the deal as evidence of "the continued growth of our investment banking and capital markets platform." Moe Cohen, who heads investment banking at the firm, pointed to the bank's relationships among biotechnology investors.

Being the **sole book-running manager** means Jones alone ran the order book and allocated shares, rather than sharing that role with other banks — an arrangement more common on smaller offerings than on large syndicated ones.

Detailed financials, pipeline status and post-offering share count for Vogenx would appear in the company's registration statement and its first quarterly report as a public company, neither of which is summarised in the release.

Source: [PR Newswire](https://www.prnewswire.com/news-releases/jones-served-as-sole-book-running-manager-for-vogenxs-81-3-million-initial-public-offering-302853039.html?ref=pennystocks.news)

*This article is journalism, not investment advice. It is not an offer or solicitation to buy or sell any security. Micro-cap and penny stocks carry a high risk of loss, including illiquidity and dilution. Do your own research.*